American Thoracic Society - Sanofi Investor Call
sanofi
Lung function improvement corroborates SAR'765 mode of action
Pre-BD FEV1
change from baseline (L)
0,4
Placebo ■SAR443765 400 mg
0,26
0,3
0,198
0,2
0,1
0
-0,1
-0,014
0,113
0,147
0,07
Potential to suppress airway
inflammation and preserve airway
function in asthma
Rapid, numerical improvement in
FEV1 after single dose of SAR'765
• Maximal improvement in
pre-BD FEV1 at Day 8 largely
maintained throughout the 4-week
observation period
-0,2
Baseline
Day 8
Day 15
Placebo, n
SAR443765, n
12
24
12
23
12
24
Day 29
12
24
FEV1 measured in triplicate. If the difference between the 2 largest FEV1 values was ≥0.150 L,
the triplicate set was excluded. Maximal FEV1 value from the triplicate used for analysis.
PD, pharmacodynamic; FEV1, forced expiratory volume in 1 second; BD, bronchodilator SEM, standard error of the mean.
42 ATS Investor CallView entire presentation